TRAF2 and bladder transitional cell carcinoma: In bladder urothelial carcinoma (BC), receptor-interacting protein kinase 4 (RIPK4) promotes TRAF2 and subsequent NF-κB signaling pathway, ultimately, promotes BC cell aggressiveness [24].